dextranomer

Dextranomer
Systematic (IUPAC) name
	Dextran, 2,3-dihydroxypropyl 2-hydroxy-1,3-propanediyl ethers
Clinical data
Trade names	Debrisan
AHFS/Drugs.com	International Drug Names
Routes of; administration	Topical
Identifiers
CAS Registry Number	56087-11-7
ATC code	D03AX02
PubChem	SID: 214362
(what is this?) (verify)

デキストラノマー

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/24 15:39:22」(JST)

wiki en

[Wiki en表示]

Dextranomer (trade name Debrisan) is a cicatrizant used in dressings for wound healing,^[1] and in pharmaceutical products to treat fecal incontinence.^[2] It consists of dextran polymer chains cross-linked into a three-dimensional network.^[3]

Solesta

Solesta is the marketed brand name of a system of injections of dextranomer in stabilized sodium hyaluronate for use in fecal incontinence (FI).^[4] This preparation is a biocompatible gel, for use as a perianal injectable bulking agent. The system is intended to be injected in the submucosal layer of the proximal anal canal (i.e. above the level of the dentate line).

References

^ Parulkar BG, Sobti MK, Pardanani DS (1985). "Dextranomer dressing in the treatment of infected wounds and cutaneous ulcers". J Postgrad Med 31 (1): 28–33.
^ Solesta Gel Approved for Fecal Incontinence
^ Solesta Package Insert
^ Hoy, SM (Aug 20, 2012). "Dextranomer in stabilized sodium hyaluronate (Solesta): in adults with faecal incontinence.". Drugs 72 (12): 1671–8. doi:10.2165/11209030-000000000-00000. PMID 22845415.

External links

dextranomer at the US National Library of Medicine Medical Subject Headings (MeSH)

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における便失禁：マネージメント fecal incontinence in adults management
2. 膀胱尿管逆流のマネージメント management of vesicoureteral reflux
3. 女性における腹圧性尿失禁：外科的治療後の症状の持続または再発 stress urinary incontinence in women persistent recurrent symptoms after surgical treatment
4. 成人における便失禁：疫学および評価 fecal incontinence in adults etiology and evaluation

English Journal

The Biocompatibility of a Cellulose Exopolysaccharide Implant in the Rabbit Bladder When Compared With Dextranomer Microspheres Plus Hyaluronic Acid.

Lima SV1, de Oliveira Rangel AE2, de Melo Lira MM3, Pinto FC4, Campos Júnior O4, Sampaio FJ5, de Andrade Aguiar JL6.
Urology.Urology.2015 Apr 11. pii: S0090-4295(15)00203-4. doi: 10.1016/j.urology.2015.02.028. [Epub ahead of print]
OBJECTIVE: To evaluate biocompatibility of a cellulosic exopolysaccharide (CEC) as bulking agent in rabbit urinary bladder.MATERIALS AND METHODS: The experimental study was developed at the Nucleus for Experimental Surgery or UFPE. The new agent was injected into the bladder of the adult rabbits usi
PMID 25872698

A novel use of dextranomer/hyaluronic acid copolymer.

Lambropoulos V1, Mouravas V, Papageorgiou I, Spyridakis I, Marakis G.
Urologia.Urologia.2015 Mar 20;82(1):71-3. doi: 10.5301/uro.5000065. Epub 2014 May 14.
The aim of this study is to present a novel use of Dextranomer/hyaluronic acid copolymer (Deflux) for the treatment of a complicated iatrogenic chronic urethral injury. A 12-year-old boy with a neuropathic bladder presented a groove in the urethral mucosa due to chronic clean intermittent catheteriz
PMID 24832471

Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: Does bulking substance matter?

Dogan HS1, Altan M2, Citamak B2, Bozaci AC2, Koni A2, Tekgul S2.
Journal of pediatric urology.J Pediatr Urol.2015 Mar 2. pii: S1477-5131(15)00045-5. doi: 10.1016/j.jpurol.2014.12.009. [Epub ahead of print]
INTRODUCTION: Among the interventional treatment modalities for vesicoureteral reflux (VUR), endoscopic subureteric injection seems to be the least invasive method with acceptable outcomes when applied in appropriate patients.OBJECTIVE: The aim of the presented study is to investigate the parameters
PMID 25791422

Japanese Journal

膀胱尿管逆流症に対する非動物由来安定化ヒアルロン酸ナトリウム/デキストラノマー・ゲル(NASHA^<TM>/Dxゲル)注入療法 : 日本人患者を対象とした多施設共同オープン試験

谷風三郎,長雄一,多田実 [他],合谷信行,浅沼宏,山崎雄一郎,島田憲次,杉多良文,後藤隆文,山口孝則
日本泌尿器科學會雜誌 101(5), 676-682, 2010-07-20
(目的)非動物由来安定化ヒアルロン酸ナトリウム/デキストラノマー・ゲル(NASHA^<TM>/Dxゲル)を尿管口周囲に注入する内視鏡的注入療法の有効性と安全性を評価するため,日本人膀胱尿管逆流症(VUR)患者を対象とした多施設共同オープン試験を行った.試験成績について報告する.(対象と方法)逆流グレードII〜IVの1歳以上のVUR患者にNASHA/Dxゲルを内視鏡的に注入し,注入3, …
NAID 110007682272

Nonanimal stabilized hyaluronic acid/Dextranomer Gel(Deflux^[○!R])を用いた膀胱尿管逆流症に対する内視鏡治療

藤本隆夫,諏訪智英,石井のぞみ
日本小児外科学会雑誌 46(2), 220-228, 2010-04-20
… 【目的】小児膀胱尿管逆流症患児16例,25尿管(国際分類II度4尿管,III度9尿管,IV度12尿管)に対し,nonanimal stabilized hyaluronic acid/Dextranomer Gel(Deflux^[○!R]:Q-Med)を用いた内視鏡下治療法を施行し,術後3か月,1年後の治療効果についての評価を行った.【対象および方法】治療施行時年齢は6か月〜5歳8か月(平均2歳2か月)である.尿管口へのDeflux^[○!R]の注入はHydrodistension Implantation Technique法を用いた.【結果】平均手術時間は19.9±11.3分,Deflux^[ …
NAID 110007593917

腹圧性尿失禁の既往をもち診断困難であった医原性尿管膣瘻の1例

渡辺美穂,山西友典,釜井隆男 [他],古谷信隆,福田武彦,吉田謙一郎
泌尿器科紀要 55(11), 721-724, 2009-11
… Periurethral injection with non-animal stabilized hyaluronic acid/ dextranomer was performed. …
NAID 120001712081

Related Pictures

[1] Parulkar BG, Sobti MK, Pardanani DS (1985). "Dextranomer dressing in the treatment of infected wounds and cutaneous ulcers". J Postgrad Med 31 (1): 28–33.

[2] Solesta Gel Approved for Fecal Incontinence

[3] Solesta Package Insert

[Hoy_2012-4] Hoy, SM (Aug 20, 2012). "Dextranomer in stabilized sodium hyaluronate (Solesta): in adults with faecal incontinence.". Drugs 72 (12): 1671–8. doi:10.2165/11209030-000000000-00000. PMID 22845415.

匿名

検索

案内

案内